BioRestorative Therapies, Inc.
BRTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.8M
$2.27
▼ -2.58%
P/E
—
Mkt Cap
$3.8M
52-Wk Range
$2.25–$34.60
52-Week Range
$2.25 - $34.60
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 92.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary autologous stem cell technology with completed Phase 1 clinical data
- Strategic partnerships with pharmaceutical leaders including Pfizer and academic institutions
- Specialized curved needle delivery device for precise cellular administration
- Dual therapeutic programs addressing large, underserved patient populations
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Advancement of BRTX-100 through Phase 2/3 clinical trials toward market approval
Value
Valuation data unavailable
Momentum
Falling
-73.0% over 3m
Quality
Excellent
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying BRTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 29, 2026
Most recent quarter reported revenue of $23.2K. Reported EPS of -$1,215.27.
Reported EPS · last 4Q
Q1 26
-$1,215.27
Q4 25
-$0.36
Q3 25
-$0.33
Q2 25
-$0.30
Revenue trend · last 8Q
—
—
—
-29%
+240%
-95%
-55%
-7%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$89.1K
$233.6K
$43.3K
$25.0K
$303.3K
$11.8K
$19.6K
$23.2K
Margins · last 8Q
Gross
—
Profit
-9298.3%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How BRTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related